▶주메뉴 바로가기
▶본문 바로가기
Samsung Biologics announced Nov. 14 that it has received 27001 security certification from the Geneva-based International Organization for Standardization. The company emphasized that it is the first contract manufacturing organization to obtain ISO 27001 certification. German Ambassador to South...
Korean biotech firm Hugel announced Nov. 12 that its operating profit jumped 225 percent in the third quarter from a year earlier to 18.2 billion won ($15.57 million). Its sales increased by 46.4 percent to 51.1 billion won. Hugel said its overall profit improved recently due to the sales growth ...
GOTTINGEN, Germany -- Behind the market expansion of Samsung’s biologics business is 149-year-old Sartorius, a German firm that has helped it grow rapidly. Founded in 1870, the German company supplies single-use bags and membrane filters on top of many others that are necessary for biopharmaceuti...
South Korean pharmaceutical firm Samsung Bioepis said Nov. 7 it has entered into a new commercialization agreement worth $370 million with US partner Biogen. Under the partnership, Biogen will be responsible of marketing and sales of Samsung Bioepis’ two ophthalmology biosimilars -- SB11 and S...
Celltrion announced on Nov. 5 that it will start phase 3 clinical trials of its patch-type donepezil, a medication that aims to treat people with Alzheimer’s disease, jointly with local drugmaker Icure. Established in 2000, Icure is a Kosdaq-listed firm that possesses more than 50 patents related...
Bio company SillaJen announced Oct. 31 it will pay back 110 billion won (94.25 million), which it received by issuing convertible bonds, to Kiwoon Securities in March. “The annual interest rate for convertible bonds that were issued, including the ones issued to Kiwoon, rose from 3 to 6 percent a...
South Korea’s Health Ministry said Oct. 30 that it is considering revoking Kolon Life Science’s innovative drug company certification for mislabeling and falsely reporting ingredients in its gene therapy drug, Invossa. A key material used in Invossa came from a kidney cell instead of from car...
Sales of biosimilar Remsima by South Korean bio-pharmaceutical firm Celltrion reached $77 million in the United States during the third quarter of this year, industry data showed Oct. 30. Sales of the biosimilar drug to treat autoimmune diseases jumped 8 percent on-year during the July-Septembe...
The 30th CPhI Worldwide 2019, the biggest global event of the year for the pharmaceutical industry, is set to take place at Messe Frankfurt in Germany from Nov. 5 to 7. Every year, CPhI brings together more than 100,000 pharmaceutical professionals to network for business opportunities at venues a...
South Korean biotech firm Bridge Biotherapeutics announced Oct. 25 that it had received preliminary screening approval for Kosdaq listing. The company applied for approval Sept. 3 and expects to be listed on the second-tier Kosdaq market in December this year. “We will continue to develop and ad...
The Ministry of Food and Drug Safety on Oct. 16 ordered Medytox to withdraw and dispose of the entire batch of its botulinum toxin Meditoxin produced for exports. The problematic products were produced on Oct 6, 10 and 19 of 2016 and its expiry date is Oct 5, 11 and 18 this year, respectively. The...
Daewoong Pharmaceutical announced Oct. 16 it has launched its botulinum toxin under the name Nuceiva in Canada. It is the first South Korean company to enter the Canadian market with a botulinum toxin brand. “Like the US market, Canada also has only three types of botulinum toxins which have bee...
South Korea’s Supreme Court announced on Oct. 16 that it has approved a request by Samsung BioLogics to suspend the execution of penalties by the financial watchdog on Oct. 11. The court’s recent decision came after the lower courts approved the same request of Samsung BioLogics in February an...
Daewoong Pharmaceutical on Oct. 7 denied allegations by Medytox that it stole manufacturing secrets, including its Hall A Hyper strain, to develop its botulinum toxin Nabota. “Medytox is saying that its Hall A Hyper strain, which was proven to not form spores by multiple professionals for decades...
South Korean drugmaker Daewoong Pharmaceutical said Oct, 2 it has won approval from European authorities for the sale of its botulinum toxin product. The European Commission accepted Daewoong’s application to sell Nabota, Korea’s first botulinum toxin product to receive the green light for th...
Posco threads new life to old uniforms for Philippine communities
NCSoft releases sustainability report to meet global green standards
Samsung may supply advanced image sensors for Apple: analyst
Hana chief cleared of severe punishment in DLF crisis
NCSoft launches official Discord channel for Throne and Liberty
Qoo10 liquidity crisis sparks massive complaints, fears of wider damage